SCHEMBL3309985

SCHEMBL3309985

CNc1ccc(-c2ccc3scnc3c2)cn1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.48
PIK3CD O00329 1/20 0.44
RIPK2 O43353 7/20 0.43
KDR P35968 2/20 0.43
TGFBR1 P36897 2/20 0.43
EGFR P00533 1/20 0.43
LCK P06239 1/20 0.42
MCL1 Q07820 2/20 0.41
RIPK3 Q9Y572 3/20 0.41
DYRK2 Q92630 2/20 0.41
WNT1 P04628 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
FFAR1 O14842 1/20 0.40
MAP3K11 Q16584 1/20 0.40
FASN P49327 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28048502 0.80 ALDH1A1 (0.54) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL1849707 0.80 RIPK2 (0.52) APPPIK3CDRIPK2KDRTGFBR1
SCHEMBL1854129 0.76 CYP2A6 (0.45) APPPIK3CDRIPK2KDRTGFBR1
SCHEMBL13394572 0.76 PFKFB3 (0.46) APPPIK3CDRIPK2KDRTGFBR1
SCHEMBL3306678 0.76 RIPK2 (0.49) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL13394552 0.75 ALOX5AP (0.49) APPPIK3CDRIPK2KDRTGFBR1
SCHEMBL6650934 0.74 FFAR1 (0.48) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL3301474 0.74 RIPK2 (0.43) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL3308095 0.73 PIK3CA (0.53) PIK3CDRIPK2KDRTGFBR1EGFR
SCHEMBL3299110 0.73 PIK3CD (0.41) PIK3CDRIPK2KDRTGFBR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB APP 1/4885PIK3CD 4367/4885RIPK2 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.